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Research
During the last few decades, evidence con-
cerning the role of chromosomal aberrations 
(CA) in carcinogenesis has been enriched by 
a number of epidemiologic studies showing 
that high CA frequencies in peripheral blood 
lymphocytes of healthy individuals are asso-
ciated with increased cancer risk (Boffetta 
et al. 2007; Bonassi et al. 1995, 2000; 2004; 
Brøgger et al. 1990; Hagmar et al. 1994, 
1998, 2004; Liou et al. 1999; Rossner 
et al. 2005). A case–control study nested 
within ESCH (European Study Group of 
Cytogenetic Biomarkers and Health) cohort 
studies (Bonassi et al. 1995; Hagmar et al. 
1994, 1998) found that the strength of such 
association is not influenced by occupa-
tional exposure to carcinogens or tobacco 
smoking (Bonassi et al. 2000). Contrasting 
results were reported by other investiga-
tions, such as a cohort study on Czech work-
ers (Smerhovsky et al. 2002) describing a 
stronger association between CA frequency 
and cancer incidence in miners exposed to 
radon. Whether the CA–cancer association 
reflects (occasionally undetected) exposure 
to carcinogens, individual susceptibility to 
carcinogens, some form of chromosomal 
instability, or a causal role of chromosomal 
rearrangements in the carcinogenic process is 
still an open issue.
A striking amount of data supports the 
hypothesis that individual characteristics 
associated with cancer risk, such as inherited 
differences in metabolic enzymes or DNA 
repair capacity, may also modify CA occur-
rence (Norppa 2004). These findings raise the 
obvious question of whether the association 
between CA and cancer risk depends on indi-
vidual metabolism and DNA repair capabil-
ity, so that CA would better predict cancer 
risk in people with an unfavorable genotype. 
This question can be assessed by incorporat-
ing genotype data to the CA–cancer studies, 
but such an approach has not been applied 
previously, as DNA samples have not been 
readily available.
Among the most frequently studied poly-
morphisms are those concerning the metabo-
lism of xenobiotics, in particular glutathione 
S-transferases (GSTs). GSTs catalyze the 
conjugation between glutathione and reac-
tive xenobiotic compounds in a pathway that 
leads to thioethers excreted in the urine (Bolt 
and Thier 2006; Parl 2005). The major bio-
logical function of GSTs is considered to be 
protection against electrophilic chemical spe-
cies, although metabolic activation involving 
GST-mediated glutathione conjugation has 
also been described (e.g., for some chlorin-
ated substrates) (Bolt and Thier 2006; Parl 
2005). Detoxification by glutathione con-
jugation can represent a minor (e.g., styrene 
oxide) or a major (e.g., benzo[a]pyrene) met-
abolic pathway for many genotoxic agents. 
Given the importance of GSTs in the detoxi-
fication of electrophilic carcinogens, the pos-
sible influence of polymorphisms in GST 
genes on cancer risk has been investigated 
extensively (Bolufer et al. 2006; Bolt and 
Thier 2006; Carlsten et al. 2008; Hiyama 
et al. 2008; Parl 2005; Shi et al. 2008; Vineis 
et al. 2007; White et al. 2008). The GST M1 
(GSTM1; BC036805, GenBank) and theta 
1 (GSTT1; X79389, GenBank) genes have 
received much attention because of the high 
prevalence of homozygous deletions result-
ing in null genotypes with a decreased ability 
to detoxify carcinogenic compounds, plac-
ing null individuals at increased cancer risk 
(Bolufer et al. 2006; Bolt and Their 2006; 
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Ba c k g r o u n d: The frequency of chromosomal aberrations (CA) in peripheral blood lymphocytes of 
healthy individuals has been associated with cancer risk. It is presently unclear whether this associa- hether this associa-
tion is influenced by individual susceptibility factors such as genetic polymorphisms of xenobiotic-
metabolizing enzymes.
oBjectives: To evaluate the role of polymorphisms in glutathione S-transferase (GST) M1 
(GSTM1) and theta 1 (GSTT1) as effect modifiers of the association between CA and cancer risk.
Me t h o d s : A case–control study was performed pooling data from cytogenetic studies carried out 
in 1974–1995 in three laboratories in Italy, Norway, and Denmark. A total of 107 cancer cases 
were retrieved from national registries and matched to 291 controls. The subjects were classified as 
low, medium, and high by tertile of CA frequency. The data were analyzed by setting up a Bayesian 
model that included prior information about cancer risk by CA frequency.
re s u l t s: The association between CA frequency and cancer risk was confirmed [ORmedium (odds 
ratio)medium = 1.5, 95% credibility interval (CrI), 0.9–2.5; ORhigh = 2.8, 95% CrI, 1.6–4.6], whereas 
no effect of the genetic polymorphism was observed. A much stronger association was seen in the 
Italian subset (ORhigh= 9.4, 95% CrI, 2.6–28.0), which was characterized by a lower technical vari- technical vari-
ability of the cytogenetic analysis. CA level was particularly associated with cancer of the respiratory 
tract (ORhigh= 6.2, 95% CrI, 1.5–20.0), the genitourinary tract (ORhigh = 4.0, 95% CrI, 1.4–10.0), 
and the digestive tract (ORhigh = 2.8, 95% CrI, 1.2–5.8). 
co n c l u s i o n s: Despite the small size of the study groups, our results substantiate the cancer risk 
predictivity of CA frequency, ruling against a strong modifying effect of GSTM1 and GSTT1 
  polymorphisms.
key w o r d s : Bayesian, biomarker, cancer risk, case–control study, chromosomal aberration, genetic 
polymorphism, glutathione S-transferase, GSTM1, GSTT1, Monte Carlo Markov Chain. Environ 
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Hiyama et al. 2008; Parl 2005; Shi et al. 
2008; White et al. 2008).
The availability in the ESCH database of 
a group of subjects genotyped for GSTM1 
and GSTT1 genes in three national labora-
tories allowed us to address the question if 
these genetic polymorphisms can modify the 
strength of the association between CA and 
cancer risk. In a group of subjects from Pisa, 
Italy—not included in the original ESCH 
database—cytogenetic slides could be retrieved 
from freezers, stained, and scored all together, 
minimizing the impact of protocol variation, 
reagents drift, and scorer heterogeneity.
The small size of study groups is a com-
mon limitation of biomarker validation 
studies. The presence of sparse data and miss- sparse data and miss-
ing covariates are conditions for which the 
Bayesian paradigm presents some advantages 
over the frequentist paradigm. In particular, 
Bayes’ rule opens the possibility of improving 
the estimation of the parameters of interest 
by including the prior proba  bility, based on 
knowledge already available—in this case, the 
association of CA with cancer risk.
This study aimed at a) confirming the 
presence of the association between CA and 
cancer risk in a partially new data set, and b) 
evaluating the role of GSTM1 and GSTT1 
polymorphisms as effect modifiers of this 
association. Ancillary but still important aims 
were to evaluate the impact of reduced labo-
ratory/technical variability on risk estimates 
and to verify whether Bayesian statistics can 
provide reliable estimates in small strata.
Material and Methods 
Subjects. A nested case–control study was 
performed pooling data from cytogenetic 
surveillance studies carried out from 1974 
to 1995 at the Department of Biology, 
University of Pisa, Pisa, Italy; the Department 
of Occupational Medicine, Telemark 
Hospital, Skien, Norway; and the Danish 
National Institute of Occupational Health, 
Copenhagen, Denmark. These laboratories 
analyzed GSTM1 and GSTT1 polymorphisms 
in subjects screened for CA and followed up 
in the framework of the ESCH (Bonassi et al. 
2000; Hagmar et al. 1998, 2004) and the more 
recent CancerRiskBiomarkers (Cytogenetic 
Biomarkers and Human Cancer Risk) (Norppa 
et al. 2006) collaborative projects.
The Italian cohort consisted of 1,650 
healthy subjects selected from the general popu-
lation living in three areas in Tuscany (Pisa, 
Cascina, and Navacchio) enrolled between 
1991 and 1993 (Barale et al. 1998a, 1998b; 
Landi et al.1999; Milillo et al. 1996). The 
Norwegian cohort included 681 healthy sub-
jects, either occupationally exposed or referents, 
collected between 1974 and 1990 (Brøgger 
et al. 1990; Hansteen et al. 1978, 1984). The 
Danish data arose from a biomonitoring study 
conducted in 1987 in a group of 226 male 
stainless steel welders and referents (Knudsen 
et al. 1992). Information was gathered on 
demographic, occupational, and lifestyle   factors 
at the time of blood sampling.
In the Nordic countries, all malignant 
tumors diagnosed from the date of CA test-
ing until the end of the follow-up (2006 
in Norway, and 2003 in Denmark) were 
retrieved through linkage from national can- through linkage from national can- from national can- national can-
cer registries. In Italy, the cause of death was 
obtained from the municipality of residence 
(2006). At the end of the follow-up, a total 
of 107 cancer cases with information about 
GST polymorphism were tracked (105/107 
cases genotyped for GSTM1 and 77/107 for 
GSTT1). Within each national cohort, con-
trols were matched with their corresponding 
case by sex, age (± 10 years), and year of CA 
test (± 5 years). The overall cases to controls 
ratio was around 1:3 (107 cases/291 controls).
In all participating laboratories, the stand- he stand-
ard cytogenetic protocol was applied using 
heparinized whole blood and harvesting the 
cells after 48 hr of culture (Buckton and Evans 
1973). CA preparations were stained with 
Giemsa. In Italy, the slides were banked at 
–20°C at the time of the original cytogenetic 
study (1991–1993) and stained in Giemsa 
immediately before the new CA analysis. In 
Italy, 150 and in Denmark, 100 metaphases 
per donor were scored for CA by a single 
scorer. In Norway, 100 or (in more recent 
studies) 200 cells per subject were scored by 
the same three microscopists. Savage’s clas-
sification criteria for CA were used (Savage 
1976). Total CA was defined as the number 
of cells with aberrations, excluding gaps, per 
100 cells. To standardize for interlaboratory 
variation, all subjects were classified as low 
(1–33 percentile), medium (34–66 percen-
tile), or high (67–100 percentile) according 
to tertiles of CA frequency distribution. More 
details on the laboratory protocols can be 
found in previously published reports (Barale 
et al. 1998a, 1998b; Bonassi et al. 2000; 
Hagmar et al. 1994, 1998, 2004; Hansteen 
et al. 1978, 1984; Knudsen et al. 1992; Landi 
et al. 1999; Milillo et al. 1996). The study 
protocols were approved by the ethics com-
mittees and legal authorities in each country.
DNA extraction and genotype analysis. In 
Italy, genomic DNA was extracted from frozen 
whole blood or serum as described by Murgia 
et al. (2007). In Norway, DNA was extracted 
from fixed cell suspensions with the method 
described by Skjelbred et al. (2006). When 
cell suspensions were not available, DNA was 
extracted from unstained slides kept at room 
temperature for 3–26 years. The slides were 
hydrated, dried carefully before adding 100 
µL buffer (50 mM Tris, 1 mM EDTA, 0.5% 
Triton 100), covered with plastic film, kept for 
15 min at 56°C, scraped in 50–100 µL dH2O 
2–4 times (total volume 200 µL), and cen-
trifuged at 3,000 × g for 5 min; 50 µL buffer 
(as above) and 5 µL proteinase K (20 mg/
mL) were added to the pellet. The samples 
were kept on a Thermomixer (Eppendorf, 
Hamburg, Germany) at 56°C, 1,000 rpm for 
3 hr, before deactivating the enzyme on the 
Thermomixer at 96°C, 1,000 rpm for 10 min. 
The suspensions were stored at –20°C. The 
success rate depended upon the amount of 
cells, the age of the slides, and the genotype 
tested. In Denmark, DNA from mononuclear 
blood cells, originally analyzed for DNA repair 
by the unscheduled DNA synthesis technique 
and stored frozen in 0.4 M phosphate buffer 
in 1987, was used for the genotyping. This 
DNA had been isolated by using Millipore 
(Bedford, MA, USA) Microcon YM-30 cen-
trifugal filter devices.
In Italy, genotype analysis was performed 
by a specific multiplex GSTT1/GSTM1 PCR 
assay as described by Murgia et al. (2007). 
In Norway, polymorphisms of the GSTM1 
and GSTT1 (and GSTP1) genes were ana-
lyzed simultaneously by multiplex polymer-
ase chain reaction using primers described 
by Nedelcheva Kristensen et al. (1998). A 
detailed report of the methods used for geno-
typing the Danish samples can be found in 
Ko et al. (2000).
Statistical analysis. As the response vari-
able in the study was binary (cancer yes/
no), we used the standard logistic regression 
approach in which the response variable is 
the log odds (or logit). The purpose was to 
estimate the probability that the ith person 
will develop a cancer, conditionally on the 
information about his/her CA frequency Ei 
[1 = L (low), 2 = M (medium), 3 = H (high)], 
age Ai, sex Ei, and smoking habit Si, which are 
the design variables (M1):
  logit (pi) = β0 + β1Ei2+ β2Ei3  
   + β3Gi + β4Ai + β5Si.  [1]
To perform the analysis, we used the Gibbs 
sampler, which is a Monte Carlo Markov Chain 
(MCMC) sampling algorithm. MCMC is a 
class of methods for sampling from probability 
distributions based on constructing Markov 
chains. The iterative procedure simulates a 
Markov chain, which has the desired posterior 
distribution as its stationary distribution.
We used the statistical software WinBUGS 
(http://www.mrc-bsu.cam.ac.uk) (Lunn et al. 
2000) to set up a Bayesian model specify-
ing an informative normal prior distribution 
for the regression coefficients where existing 
knowledge was available. More precisely, from 
the pooled cohort analysis of 22,358 subjects 
examined for CAs in 11 countries (Bonassi 
et al. 2008), we knew that the overall odds 
ratio (OR) for the medium tertile compared 
with the low was 1.3 with a 95% confidence CA, cancer risk, and genetic polymorphism
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interval (CI) of 1.07–1.60, and that the OR 
for the highest tertile was 1.4 (1.16–1.72). 
The assumption that the log OR is normally 
distributed leads to a normal distribution with 
mean value given by ln(1.3) = 0.26 and ln(1.4) 
= 0.33, respectively. The standard deviation of 
the normal distributions was found by solv-
ing the equations 1n(1.3) + 1.96σ = 1n(1.60) 
and 1n(1.4) + 1.96 σ = 1n(1.72), which gave 
a standard deviation on the log odds scale of 
0.1 in both cases. As suggested by Birkes and 
Dodge (1993) and Gelman et al. (1995), a 
simple way to provide a prior variance on the 
parameters β1 and β2 in the current study was 
to inflate the historical variance. To take into 
account the heterogeneity and other differ-
ences between current and historical data, we 
considered the prior variance as a Gamma ran-
dom variable which, on average, fluctuated 
around the inflating factor (60 in our case). 
Further prior information was obtained from 
International Agency for Research on Cancer 
(IARC) mono  graph on tobacco smoking 
(IARC 1986): (weighted) mean value of OR 
(current vs. never smokers) was considered 10 
for lung cancer, 1.4 for oral cavity–digestive 
tract cancers, and 2.1 for genitourinary organ 
cancers. With regard to the Bayesian interval 
estimation of OR, we adopted the 95% cred-
ibility interval (CrI) with the highest posterior 
density, that is, an interval of the OR posterior 
distribution such that the area under the curve 
is 0.95 and the density at any point inside the 
interval is greater than the density at any point 
outside. The traditional CI based on frequen-
tist inference refers to repeated sampling, ran-
dom intervals, and true parameter values (OR) 
and does not provide any estimates concerning 
the study that was actually conducted. On the 
contrary, CrI is a probability statement within 
the data set studied concerning the random 
variable OR and specifying the range within 
which the OR lies with 0.95 probability.
To estimate if the GSTM1 null and 
GSTT1 null genotypes were a risk factor for 
all cancers, we used a similar multivariate anal-
ysis, adding to the model M1 described in 
Equation 1 the variables GSTM1, GSTT1 (we 
called this model M2) and their interactions 
within CA (we called this model M3). The 
analysis performed to choose between compet-
ing models was based on the BIC index, BIC = 
–21nLm + m1nn, where n is the sample size, m 
is the difference of the number of parameters 
in the models, and Lm is the likelihood ratio 
for the models. This criterion penalized mod-
els that improved the fit, increasing the num-
ber of parameters. The model with the lower 
value of BIC was the one to be preferred.
Results
The distribution of cases and controls in the 
whole database by country and by other vari-
ables considered in the analysis is given in 
Table 1. The proportion of males and of cur-
rent smokers was higher in the databases from 
Norway and Denmark. Smoking habit was 
not different between the cases and controls. 
The Italian subjects selected from the general 
population had a higher mean age, a higher 
proportion of women, and fewer current 
smokers than the Nordic groups. The distri-
bution by tumor site of the 107 cancer cases 
included in the study is reported in Table 2.
The distribution of GST polymorphisms 
did not differ significantly in the three coun-
tries, and therefore all data were combined 
before analysis (Table 3). No significant dif-
ferences were evident in the genotype distribu-
tion of cases and controls, with null genotype 
prevalence of 52.4 and 50.5% for GSTM1 
and 29.9 and 29.8% for GSTT1, respectively. 
Accordingly, the mean frequency of CA did not 
appear to be modulated by genotype (Table 3).
Table 1. Number of cancer cases and controls classified according to sex, age, and smoking status. 
    Italy  Norway   Denmark  Total
Group  Case/control  Total  Case/control  Total  Case/control  Total  Case/control  Total (%)
Sex           
  Male  21/48  69  64/165  229  12/49  61  97/262  359 (90.2)
  Female  8/23  31  2/6  8  0/0  0  10/29  39 (9.8)
Age (years)          
  ≤ 39  0/0  0  13/44  57  5/16  21  18/60  78 (19.6)
  40–47  2/5  7  12/41  53  1/19  20  15/65  80 (20.1)
  48–55  1/13  14  20/39  59  4/10  14  25/62  87 (21.9)
  56–61  9/20  29  7/34  41  2/4  6  18/58  76 (19.1)
  ≥ 62  17/33  50  14/13  27  0/0  0  31/46  77 (19.3)
Smokinga         
  Never  13/28  41  25/61  86  4/22  26  42/111  153 (38.4)
  Former   9/23  32  7/21  28  5/19  24  21/63  84 (21.1)
  Current   7/20  27  33/81  114  3/8  11  43/109  152 (38.2)
  Total  29/71  100  66 /171  237  12/49  61  107/291  398 (100)
aAt the time of CA sampling. For one case and eight controls from Norway, no data were available on smoking status.
Table 2. Distribution of cancer cases included in the nested case–control study by site and country.
  No. of cases  Percent of all
Tumor site (ICD–9 code)a  Italy  Norway  Denmark  Total  cases
Oral cavity (140–149)  0  1  1  2   1.9
Esophagus (150)  1  0  0  1   0.9
Stomach (151)  1  3  0  4   3.7
Intestine, colon, and rectum (152–154)  4  8  1  13   12.1
Liver (155)  3  2  0  5   4.7
Pancreas (157)  4  1  0  5   4.7
Larynx (161)  0  1  0  1   0.9
Lung (162)  6  5  1  12   11.2
Bone, skin (170–173)  0  19  1  20   18.7
Breast (174)  2  0  0  2   1.9
Uterus (179,182)  1  0  0  1   0.9
Ovary (183)  0  1  0  1   0.9
Prostate (185)  1  6  0  7   6.5
Bladder (188)  2  4  1  7   6.5
Kidney (189)  1  2  0  3  2.8
Other sites   3  13  7  23  21.5
Total   29  66  12  107  100.0
aInternational Classification of Diseases, 9th Revision (WHO 1975).
Table 3. Distribution of GSTM1 and GSTT1 genotypes in cases and controls and mean CA frequency.a
               Two-sample
              Kolmogorov–Smirnov 
              test of identical
  Total  Mean CA %  distribution functions
Genotype  Cases (%)  Controls (%)  Total (%)  Cases (SE)   Controls (SE)  Total (SE)  (null vs. positive)
GSTM1      
  Null  55 (52.4)  141 (50.5)  196 (51)  2.13 (0.2)  1.42 (0.1)  1.62 (0.1)  p = 0.69
  Positive  50 (47.6)  138 (49.5)  188 (49)  1.83 (0.2)  1.47 (0.1)  1.57 (0.1) 
  All  105  279  384    
GSTT1      
  Null  23 (29.9)  65 (29.8)  88 (29.8)  1.78 (0.36)  1.20 (0.15)  1.35 (0.2)  p = 0.67
  Positive  54 (70.1)  153 (70.2)  207 (70.2)  1.80 (0.17)  1.46 (0.12)  1.55 (0.1) 
  All  77  218  295   
aBecause of the limited amount of DNA retrieved from stored specimen, only 105/107 cases were genotyped for GSTM1 
and 77/107 for GSTT1.Rossi et al.
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The univariate analysis comparing the 
overall mean CA frequency (SE) in cases and 
controls [1.98 (0.14) vs. 1.38 (0.14)] revealed a 
highly significant difference (t-test, p = 0.006). 
At the national level, cancer cases had a sig-
nificantly higher mean CA frequency in the 
Danish and Italian databases (data not shown).
The results of the multivariate Bayesian 
model linking CA tertile and cancer risk are 
reported in Table 4. No effect of sex or age were 
observed; smoking habit increased the overall 
risk of cancer but did not confound or modify 
the effect of CA level on cancer risk. The overall 
analysis showed a borderline risk increase for 
subjects in the medium tertile of CA distri-
bution (OR = 1.5; 95% CrI, 0.88–2.50) and 
an increase for those in the high tertile (OR = 
2.8; 95% CrI, 1.6–4.6) when compared with 
the lowest tertile. Increased cancer risks for the 
medium and high tertiles were found in all 
national data sets, although only in the high-
est tertile of the Italian subset did the CrI not 
include 1 (OR = 9.4; 95% CrI, 2.6–28.0).
The possible role of GSTM1 and GSTT1 
genetic polymorphisms as effect modifiers of 
the association between CA frequency and 
cancer risk was tested in the Bayesian mod-
els (model M3 vs. model M2). The analysis, 
based on the BIC index, favored the model 
without interaction terms (M2), ruling against 
the hypothesis that the cancer risk predictivity 
of CA frequency could be modified by these 
polymorphisms, i.e., BIC(M3) = 481.9 > 
BIC(M2) = 473.1 for GSTM1 and BIC(M3) 
= 365.5 > BIC(M2) = 357.7 for GSTT1.
A similar multivariate model was used to 
estimate if the GSTM1 null and GSTT1 null 
genotypes were a risk factor for all cancers 
(model M2 vs. model M1). Again, the BIC 
index did not show any increase in the null 
genotypes, as anticipated by the results of the 
univariate analysis, i.e., BIC(M2) = 473.1 > 
BIC(M1) = 467.3 for GSTM1 and BIC(M2) 
= 357.7 > BIC(M1) = 352.6 for GSTT1.
Finally, we fitted multivariate Bayesian 
models to major cancer sites to test the hypoth-
esis that CA frequency could more specifi-
cally predict the risk by cancer type (Table 5). 
Credible associations (see statistical methods 
for a definition of credibility intervals) were 
found with the high tertile of the CA distribu-
tion for cancers of the genitourinary tract (OR 
= 4.0; 95% CrI, 1.4–10.0); respiratory tract 
(OR = 6.2; 95% CrI, 1.5–20.0), and digestive 
tract (OR = 2.8; 95% CrI, 1.2–5.8).
Discussion
The results of this case–control study provide 
new information for the validation of CA as a 
biomarker of cancer risk. Although the study 
groups were rather small, our findings sug-
gest that the association between CA and can-
cer is not modified by GSTM1 and GSTT1 
polymorphisms, that the association is higher 
when the evaluation is based on uniform cyto-
genetic data rather than pooled historical data, 
and that the use of Bayesian modeling is a 
credible approach for risk estimation in case of 
sparse data, a common condition in biomarker 
validation studies.
Our study offered a rare opportunity to 
assess the impact of genetic polymorphisms on 
the relationship between chromosomal dam-
age and cancer risk with a longitudinal design. 
We were able to evaluate only two genotypes, 
that is GSTM1 and GSTT1, because of the 
limited amount of DNA available for each 
subject. Previous data have suggested that the 
null genotypes of both GSTM1 and GSTT1 
are associated with a slightly increased risk of 
some forms of cancer, although this does not 
appear to concern all cancers (Bolufer et al. 
2006; Bolt and Thier 2006; Carlsten et al. 
2008; Hiyama et al. 2008; Parl 2005; Shi et al. 
2008; Vineis et al. 2007; White et al. 2008). 
There is also evidence in favor of GSTM1 and 
GSTT1 genotypes affecting the level of CA in 
lymphocytes especially in smokers, although 
most studies have suggested no clear effects 
of either polymorphism on the baseline level 
of CA (Norppa 2004; Tuimala et al. 2004; 
Vodicka et al. 2004). Furthermore, the pos-
sible presence of heterogeneity in the genetic 
background of national populations, as well 
as the activation of carcinogens occasionally 
caused by polymorphic GSTs (Hu et al. 2006; 
Kligerman and Hu 2007), may have weak-
ened the associations studied. Thus, our nega-
tive findings on the modifying effect of the 
two GST polymorphisms on the association 
between CA and cancer risk seem to agree with 
the existing information about their negligible 
influence on total cancer risk and baseline CA 
level. Our conclusions are, however, limited 
by the small size of the study groups, which 
did not allow assessing possible interactions 
between genotype and smoking. Moreover, 
the genotype data were obtained using dif-
ferent sources of DNA, and thereby different 
methods, for DNA isolation and genotyping 
in the participating laboratories.
In general, the present findings confirmed, 
largely with new data, the results published by 
the ESCH in 2000 (Bonassi et al. 2000)—
that cancer prediction based on CA frequency 
is independent of smoking and exposure to 
carcinogens.
The polymorphisms of other genes, such 
as those involved in DNA repair, might have 
been relevant as well (Tuimala et al. 2004; 
Vodicka et al. 2004). However, polymor-
phisms in the DNA repair genes OGG1 
(8-oxoguanine DNA glycosylase; U96710, 
GeneBank), XRCC1 (X-ray repair comple-
menting defective repair in Chinese ham-
ster cells 1; M36089, GeneBank), XRCC3 
(X-ray repair complementing defective repair 
in Chinese hamster cells 3; AF035586, 
GeneBank), ERCC2 (exicision repair cross-
complementing rodent repair deficiency, 
complementation group 2; HGNC:3434, 
GeneBank), and the folate metabolism gene 
MTHFR (5,10-methylenetetrahydrofolate 
reductase; BC053509, GeneBank) were eval-
uated in the Norwegian data set (Skjelbred 
et al. 2006) and explained only 4–10% of the 
variance in CA, suggesting that these polymor-
phisms would not have strong effects on the 
association between CA frequency and cancer 
risk. Although many genetic polymorphisms 
have been observed to affect the level of chro-
mosome damage (Norppa 2004; Skjelbred 
et al. 2006; Tuimala et al. 2004; Vodicka et al. 
2004), single or a few genes may be expected 
to have only a small effect on CA frequency.
Most studies of CA and cancer risk have 
been multicentric, and the cytogenetic data 
generated during many years in a number of 
laboratories are subject to methodologic vari-
ability due to multiple scorers and differences 
in cell culture, slide preparation, staining, and 
analysis. A unique feature of the current Italian 
data was that the cytogenetic slides of the can-
cer cases and selected controls, originating from 
surveillance studies performed in Pisa in the 
early 1990s (Barale et al. 1998a, 1998b; Landi 
et al. 1999; Milillo et al. 1996), were retrieved 
from the freezer, stained, and consecutively 
scored for CA by a single microscopist spe-
cifically for the present study. Most probably, 
such procedure reduced technical variability, 
and this is the most likely explanation for the 
very high risk estimates in Pisa, previously 
reported only by another case–control study 
from Taiwan (Liou et al. 1999). This observa-
tion raises an interesting point concerning the 
Table 4. Multivariate Bayesian estimates of cancer risk by tertiles of CA frequency by country.a
  Italy  Norway  Denmark  Total
CA level  Case/control  OR (95% CrI)  Case/control  OR (95% CrI)  Case/control  OR (95% CrI)  Case/Control  OR (95% CrI)
Low  4/40  1.00  22/73   1.00  6/27   1.00  32/140  1.00
Medium  8/19  2.9 (0.8–8.3)  22/58  1.3 (0.7–2.3)  1/10   1.0 (0.2–2.7)  31/87  1.5 (0.9–2.5)
High  17/12   9.4 (2.6–28.0)  22/40   1.9 (1.0– 3.4)  5/12   2.0 (0.6–5.1)  44/64  2.8 (1.6–4.6)
Total  29/71     66/171    12 /49    107/291 
aEstimates based on 20,000 (MCMC) updates.CA, cancer risk, and genetic polymorphism
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use of CA as a biomarker of cancer risk. The 
cancer risk associated with a high frequency 
of CA, although consistently detected in all 
studies thus far published (Boffetta et al. 2007; 
Bonassi et al. 1995, 2000, 2004; Brøgger et al. 
1990; Hagmar et al. 1994, 1998, 2004; Liou 
et al. 1999; Rossner et al. 2005), has generally 
been low and variable. Therefore, it has been 
considered that CA can hardly be applied for 
individual risk assessment. If the findings of 
this study are confirmed, and a stronger asso-
ciation between CA frequency and cancer risk 
can be obtained by reducing technical variabil-
ity, the perspective for the use of this biomarker 
in cancer prevention may have to be rethought. 
Uniform CA analysis is a routine practice in 
cytogenetic surveillance studies, which are 
mostly interpreted at the group level, with 
the exception of radiation biodosimetry. For 
group-level evaluation, the present practice of 
scoring 100–200 cells per person is adequate, 
but it is likely not sufficient for reliable indi-
vidual CA assessment. However, if the level of 
CA had, in reality, a stronger association with 
cancer risk than has thus far been assumed, rea-
sonable individual cancer risk estimation might 
become feasible with extended CA analysis. 
At any rate, our findings lend further support 
to earlier considerations (Bonassi et al. 2005; 
Norppa et al. 2006) that the CA assay could be 
used more widely in estimating cancer risk at 
the group level.
Another innovative feature of the present 
study was the potential provided by the 
Bayesian approach for improving the reli-
ability of the estimates based on data from 
small groups, as often happens with biomarker 
validation studies. Most recent results from 
large CA cohort studies, such as the Czech 
cohort (Rossner et al. 2005) and the new 
cohort of Central and Eastern European coun-
tries (Boffetta et al. 2007), described stronger 
associations with specific cancers. In smaller 
cohorts and in case–control studies, risk esti-
mates based on classic frequentist modeling are 
likely to produce unreliable estimates in small 
strata, and any likelihood-based analysis for 
small data, or even worse, missing data, usually 
involves computationally intensive methods or 
ad hoc adjustments. Even without epidemio-
logic biases, the presence of small counts indi-
cates that large statistical biases may affect the 
point estimates (Greenland et al. 2000).
In contrast, the Bayesian analysis allows 
one to efficiently manage extra information, 
sparse data, and missing covariates. In the 
present study, MCMC sampling enabled us 
to make inferences for any sample size without 
resorting to asymptotic calculations. In many 
cases, a frequentist inference can be obtained 
as a special case of the Bayesian inference, and 
when vague prior information is used, point 
and interval estimates are similar to the fre-
quentist counterpart. However, the fundamen-
tal difference is the interpretation of intervals 
of variability associated with risk estimates. 
This is the best possible description of risk vari-
ability within the study context. If the study is 
correctly designed and the prior information is 
correctly selected, this risk range provides the 
most credible assessment of risk variability.
Interestingly, the present results showed 
the strongest associations of CA with the same 
cancer types reported by the cohort studies 
mentioned above, that is, cancers of the diges-
tive (Boffetta et al. 2007; Rossner et al. 2005) 
and respiratory tract (Bonassi et al. 1995), 
although the numbers of specific cancer cases 
in the present evaluation were small.
In conclusion, this nested case–control 
study provided relevant new information for 
interpreting the role of chromosomal dam-
age in carcinogenesis. In particular, it sug-
gested that reducing technical variability in 
the cytogenetic analysis may increase the 
strength of the association between CA and 
cancer risk, with possible implications for the 
results provided by cohort studies published 
so far, which were affected by large discrepan-
cies in laboratory protocols and scoring. The 
negative result concerning the influence of 
GSTM1 and GSTT1 polymorphisms, despite 
the intrinsic limitation due to small numbers, 
is in agreement with the idea that individual 
polymorphisms are not expected to have a dra-
matic influence on baseline CA level or overall 
cancer risk. Our findings support the hypoth-
esis that CA frequency, although indirectly 
measured in surrogate tissues, can predict the 
risk of cancer by itself as a phenotypic mani-
festation of multiple carcinogenic processes 
or as an intermediate step of a causal process. 
This conclusion is of great value for the use of 
CA as biomarker in cancer prevention policies.
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